1 / 15

Combinations of E nzymatic P rocedures with M ulticomponent C ondensations

Combinations of E nzymatic P rocedures with M ulticomponent C ondensations. Ryszard Ostaszewski a ,b a Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warszawa b Institute of Organic Chemistry, PAS, Kasprzaka 44/52, 01-224 Warszawa, Poland. Substrate

vila
Download Presentation

Combinations of E nzymatic P rocedures with M ulticomponent C ondensations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Combinations of Enzymatic Procedures withMulticomponent Condensations Ryszard Ostaszewskia,b aFaculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warszawa b Institute of Organic Chemistry, PAS, Kasprzaka 44/52, 01-224Warszawa, Poland

  2. Substrate (racemic) Substrate (meso) Enzymatic Reaction (1) Resolution of enantiomers Substrate (optically active) Product Reaction1 Multicomponent condensation. (2) Product Reaction 2 Final product Final product General concept. • Classical processes: Combination of Enzymatic Procedures with multicomponent condensation.

  3. General requirements for whole processes: • -         possibility to perform both reaction as a two - step one - pot procedure, • -         economy and simplicity, • -         easy control of the stereochemical course of reactions.

  4. Multicomponent Condensations • Ugi reaction Passerini reaction Petasis reaction

  5. Paroxetin • Yu, M. S.; Lantos, I.; Zhi-Qiang Peng, Yu J.; Cacchio T. Tetrahedron Lett.2000, 41, 5647. Holmann, M. J.; Vail, R.; Morgan, B., Sebesan, V.; Levy, C.; Dodds D. R.; Zaks, A.; Adv. Synth. Catal. 2001, 343, 744

  6. Synthetic strategy.

  7. The synthesis of 3-phenylglutaric anhydrides

  8. R = H R = Cl R = Me Solvent Time (h) Er Time(h/days) Er Time(days) Er 1 diethyl ether 114 7,2 -/17 2,5 2 diisopropyl ether 43 8,2 120/- 5,2 22 5,4 3 di-n-propyl ether 177 8,0 -/17 5,3 4 di-n-butyl ether 73 6,9 72/- 5,1 5 tertbutyl methyl ether 43 7,3 120/- 3,6 14 5,6 6 Cyclohexane 20 4,3 72/- 1,1 Desymmetrization of 3-phenylglutaric anhydrides

  9. R = H R = Cl R MeO Lipase Time (h/days) Er Time (h/days) Er Time (h/days) Er Novozyme 435 61/- 8,5 120/- 5,2 -/22 5,4 Chirazym A 19/- 10,8 -/4 5,9 -/12 6,4 Chirazym B -/9 0,80 -/4 0,7 Chirazym C -/18 5,2 Amano PS -/16 0,13 Amano PS imm. 19/- 0,13 -/4 1,4 -/7 267 SP 430 67/- 5,4 -/5 2,6 Candida cylindracea imm. -/46 1,62 Pseud. capacia imm. -/46 0,29 hog pancreas imm. -/18 0,88 Mucor miehei imm. -/46 0,35 The influence of enzyme type on desymmetrization reaction.

  10. The results of combination of enzymatic desymmetrization with Ugi Four-Component Condensation.

  11. Entry Product Solvent Yield (%) 1 i-Pr2O 0 2 i-Pr2O/MeOH, 2:1, v/v 6 3 i-Pr2O/MeOH 2:1, v/v 4 4 i-Pr2O/MeOH 2:1, v/v 6a 5 i-Pr2O/MeOH 2:1, v/v 13a

  12. Entry Product Solvent Yield (%) 1 i-Pr2O/MeOH 2:1, v/v 82 2 i-Pr2O/MeOH 2:1, v/v 81a 3 i-Pr2O/MeOH 2:1, v/v 70 a 4 i-Pr2O/MeOH 2:1, v/v 72 a 5 i-Pr2O/EtOH 2:1, v/v 80 a

  13. Passerini Reaction of 3-phenylglutaric monoesters

  14. Entry Product Solvent Yield (%) 1 i-Pr2O/EtOH 2:1 51 2 i-Pr2O/EtOH 2:1 46a 3 i-Pr2O/EtOH 2:1 35 4 i-Pr2O/EtOH 2:1 56 a 5 i-Pr2O/EtOH 2:1 35 6 i-Pr2O/EtOH 2:1 50a 7 i-Pr2O/EtOH 2:1 18%

  15. Summary • enzymatic reactions can be used with multicomponent Ugi and Passerini condensations as a two-step one-pot processes. Acknowledgments Katarzyna Jeziorska, Anna Fryszkowska, Marta Głażewska This work was supported by the State Commitee for Scientific Research (Grant 3 TO9A 081-19).

More Related